Mr. Robert Andrade reports

FENNEC PHARMACEUTICALS TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON NOVEMBER 7, 2024

Fennec Pharmaceuticals Inc. will release its third quarter 2024 financial results before the opening of United States financial markets on Thursday, Nov. 7, 2024. Management will host a conference call and webcast that day to discuss the company's financial and business results.

Conference call and webcast details

Date:  Thursday, Nov. 7, 2024

Time:  8:30 a.m. ET

To access the conference call, please register. Upon registration, a dial-in number and unique personal identification number will be provided to join the call. To access the live webcast, visit the company's website. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on the company's website for 30 days.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of Pedmark to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, Pedmark received United States Food and Drug Administration approval in September, 2022, and European Commission approval in June, 2023, and United Kingdom approval in October, 2023, under the brand name Pedmarqsi. Pedmark has received orphan drug exclusivity in the United States, and Pedmarqsi has received pediatric-use marketing authorization in Europe, which includes eight years plus two years of data and market protection.